BioXcel Therapeutics Jumps After Key Trial Success

BioXcel Therapeutics shares are trading higher after the SERENITY At-Home Phase 3 trial met its primary endpoint, supporting the sNDA submission for expanded use of IGALMI in an at-home setting.